These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 25065634)

  • 1. Reference materials for cellular therapeutics.
    Bravery CA; French A
    Cytotherapy; 2014 Sep; 16(9):1187-96. PubMed ID: 25065634
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cellular manufacturing for clinical applications.
    Sheu J; Klassen H; Bauer G
    Dev Ophthalmol; 2014; 53():178-88. PubMed ID: 24732771
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Measuring the potency of a stem cell therapeutic.
    Harper H; Rich IN
    Methods Mol Biol; 2015; 1235():33-48. PubMed ID: 25388384
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Developing assays to address identity, potency, purity and safety: cell characterization in cell therapy process development.
    Carmen J; Burger SR; McCaman M; Rowley JA
    Regen Med; 2012 Jan; 7(1):85-100. PubMed ID: 22168500
    [TBL] [Abstract][Full Text] [Related]  

  • 5. NIST bullet signature measurement system for RM (Reference Material) 8240 standard bullets.
    Ma L; Song J; Whitenton E; Zheng A; Vorburger T; Zhou J
    J Forensic Sci; 2004 Jul; 49(4):649-59. PubMed ID: 15317178
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Specificity of Good Manufacturing Practice (GMP) for Biomedical Cell Products.
    Tulina MA; Pyatigorskaya NV
    Bull Exp Biol Med; 2018 Mar; 164(4):579-582. PubMed ID: 29504094
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Design considerations for proteomic reference materials.
    Bunk DM
    Proteomics; 2010 Dec; 10(23):4220-5. PubMed ID: 21046617
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Manufacturing models permitting roll out/scale out of clinically led autologous cell therapies: regulatory and scientific challenges for comparability.
    Hourd P; Ginty P; Chandra A; Williams DJ
    Cytotherapy; 2014 Aug; 16(8):1033-47. PubMed ID: 24856894
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Good Manufacturing Practice (GMP) Translation of Advanced Cellular Therapeutics: Lessons for the Manufacture of Erythrocytes as Medicinal Products.
    McGowan NWA; Campbell JDM; Mountford JC
    Methods Mol Biol; 2018; 1698():285-292. PubMed ID: 29076098
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Manufacturing considerations for clinical uses of therapies derived from stem cells.
    Weber DJ
    Methods Enzymol; 2006; 420():410-30. PubMed ID: 17161709
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Quality Assessment and Production of Human Cells for Clinical Use.
    Fraser L; Bruce K; Campbell JM; De Sousa PA
    Methods Mol Biol; 2018; 1780():607-629. PubMed ID: 29856038
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The development of five animal feed reference materials, certified for their aflatoxin B1 content.
    Van Egmond HP; Patel S; Paulsch WE; Sizoo EA; Tuinstra LG; Wood G; Boenke A; Schurer B; Wagstaffe PJ
    Food Addit Contam; 1994; 11(4):449-77. PubMed ID: 7958115
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Matching reference materials with AOAC International methods of analysis.
    Wolf WR; DeVries J; Ikins W
    Fresenius J Anal Chem; 2001 Oct; 371(3):300-6. PubMed ID: 11688641
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Translating stem cell research from the bench to the clinic: a need for better quality data.
    Plant AL; Parker GC
    Stem Cells Dev; 2013 Sep; 22(18):2457-8. PubMed ID: 23597110
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The International Xenotransplantation Association consensus statement on conditions for undertaking clinical trials of porcine islet products in type 1 diabetes--chapter 3: Pig islet product manufacturing and release testing.
    Korbutt GS
    Xenotransplantation; 2009; 16(4):223-8. PubMed ID: 19799762
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Regulatory issues in cell-based therapy for clinical purposes.
    Casaroli-Marano RP; Tabera J; Vilarrodona A; Trias E
    Dev Ophthalmol; 2014; 53():189-200. PubMed ID: 24732772
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Potency assay development for cellular therapy products: an ISCT review of the requirements and experiences in the industry.
    Bravery CA; Carmen J; Fong T; Oprea W; Hoogendoorn KH; Woda J; Burger SR; Rowley JA; Bonyhadi ML; Van't Hof W
    Cytotherapy; 2013 Jan; 15(1):9-19. PubMed ID: 23260082
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Naturally occurring asbestos: a recurring public policy challenge.
    Lee RJ; Strohmeier BR; Bunker KL; Van Orden DR
    J Hazard Mater; 2008 May; 153(1-2):1-21. PubMed ID: 18180100
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nanoscale reference materials for environmental, health and safety measurements: needs, gaps and opportunities.
    Stefaniak AB; Hackley VA; Roebben G; Ehara K; Hankin S; Postek MT; Lynch I; Fu WE; Linsinger TP; Thünemann AF
    Nanotoxicology; 2013 Dec; 7(8):1325-37. PubMed ID: 23061887
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Strategies for Achieving Measurement Assurance for Cell Therapy Products.
    Simon CG; Lin-Gibson S; Elliott JT; Sarkar S; Plant AL
    Stem Cells Transl Med; 2016 Jun; 5(6):705-8. PubMed ID: 27386605
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.